Deutsche Bank Downgrades Xenon Pharmaceuticals to Hold, Lowers Price Target to $46

Benzinga Newsdesk www.benzinga.com Negative 91.5%

Neg 91.5% Neu 0% Pos 0%

Deutsche Bank analyst David Hoang downgrades Xenon Pharmaceuticals (NASDAQ:XENE) from Buy to Hold and lowers the price target from $90 to $46.